Biomarin Pharmaceutical Inc
$12.07B- Market cap
- $12.88B
- Debt
- +$505.32M
- Cash
- −$1.31B
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BMRN stock price vs RVMD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RVMD's multiple
Needs RVMD P/E.
Implied fair value · at BMRN's multiple
Needs EPS (TTM) is negative, BMRN P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BMRN FY 2025 (ended Dec 31, 2025) · RVMD FY 2023 (ended Dec 31, 2023). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
Capital structure 100% equity / 0% debt · EV / Revenue 3744.03x
RVMD carries the larger enterprise value at $43.36B against $12.07B; BMRN trades on the lower EV / Revenue multiple (3.75x vs 3744.03x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
0.11x
Net debt / EBITDA
Leverage against operating earnings
-1.43x
3.85x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$1.85B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
VERTEX PHARMACEUTICALS INC / MA
BMRN vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
BMRN vs ALNY
Sarepta Therapeutics, Inc.
BMRN vs SRPT
REGENXBIO Inc.
BMRN vs RGNX
IONIS PHARMACEUTICALS INC
BMRN vs IONS
PTC THERAPEUTICS, INC.
BMRN vs PTCT
AMGEN INC
BMRN vs AMGN
BRISTOL MYERS SQUIBB CO
BMRN vs BMY
GILEAD SCIENCES, INC.
BMRN vs GILD
INCYTE CORP
BMRN vs INCY
Moderna, Inc.
BMRN vs MRNA
$505.32M
$193.93M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.